0.15 USD
▲+0.00+2.24%
盘后 0.15 +0.21%
2026-11-20
市值
$9.89M
市盈率
—
EPS
-1.70
股息率
—
52 周区间
0.14 – 1.47
成交量
391.64K
Beta
1.19
目标价
1.00
52W 低 0.1452W 高 1.47
价格走势
公司简介
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It ...